789 related articles for article (PubMed ID: 21500280)
1. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.
Hanagasi HA; Gurvit H; Unsalan P; Horozoglu H; Tuncer N; Feyzioglu A; Gunal DI; Yener GG; Cakmur R; Sahin HA; Emre M
Mov Disord; 2011 Aug; 26(10):1851-8. PubMed ID: 21500280
[TBL] [Abstract][Full Text] [Related]
2. Rasagiline improves quality of life in patients with early Parkinson's disease.
Biglan KM; Schwid S; Eberly S; Blindauer K; Fahn S; Goren T; Kieburtz K; Oakes D; Plumb S; Siderowf A; Stern M; Shoulson I;
Mov Disord; 2006 May; 21(5):616-23. PubMed ID: 16450340
[TBL] [Abstract][Full Text] [Related]
3. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
Smith KM; Eyal E; Weintraub D;
JAMA Neurol; 2015 Jan; 72(1):88-95. PubMed ID: 25420207
[TBL] [Abstract][Full Text] [Related]
4. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.
Stern MB; Marek KL; Friedman J; Hauser RA; LeWitt PA; Tarsy D; Olanow CW
Mov Disord; 2004 Aug; 19(8):916-23. PubMed ID: 15300656
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
6. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease.
Leroi I; Brandt J; Reich SG; Lyketsos CG; Grill S; Thompson R; Marsh L
Int J Geriatr Psychiatry; 2004 Jan; 19(1):1-8. PubMed ID: 14716693
[TBL] [Abstract][Full Text] [Related]
7. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms.
Elmer L; Schwid S; Eberly S; Goetz C; Fahn S; Kieburtz K; Oakes D; Blindauer K; Salzman P; Oren S; Prisco UL; Stern M; Shoulson I; ;
J Neurol Sci; 2006 Oct; 248(1-2):78-83. PubMed ID: 16828804
[TBL] [Abstract][Full Text] [Related]
8. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.
Hanagasi HA
Mov Disord; 2015 Jun; 30(7):1009. PubMed ID: 25880115
[No Abstract] [Full Text] [Related]
9. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
10. CERAD test performance and cognitive impairment in Parkinson's disease.
Karrasch M; Laatu S; Martikainen K; Marttila R
Acta Neurol Scand; 2013 Dec; 128(6):409-13. PubMed ID: 23668316
[TBL] [Abstract][Full Text] [Related]
11. Cognitive impairment in Parkinson's disease without dementia.
Rodríguez-Ferreiro J; Cuetos F; Herrera E; Menéndez M; Ribacoba R
Mov Disord; 2010 Oct; 25(13):2136-41. PubMed ID: 20725913
[TBL] [Abstract][Full Text] [Related]
12. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
Parkinson Study Group
Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
[TBL] [Abstract][Full Text] [Related]
13. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.
Parkinson Study Group
Arch Neurol; 2004 Apr; 61(4):561-6. PubMed ID: 15096406
[TBL] [Abstract][Full Text] [Related]
14. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
Rascol O; Fitzer-Attas CJ; Hauser R; Jankovic J; Lang A; Langston JW; Melamed E; Poewe W; Stocchi F; Tolosa E; Eyal E; Weiss YM; Olanow CW
Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191
[TBL] [Abstract][Full Text] [Related]
15. Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial.
Weintraub D; Hauser RA; Elm JJ; Pagan F; Davis MD; Choudhry A;
Mov Disord; 2016 May; 31(5):709-14. PubMed ID: 27030249
[TBL] [Abstract][Full Text] [Related]
16. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease.
Hauser RA; Silver D; Choudhry A; Eyal E; Isaacson S;
Mov Disord; 2014 Jul; 29(8):1028-34. PubMed ID: 24919813
[TBL] [Abstract][Full Text] [Related]
17. Odor identification deficits identify Parkinson's disease patients with poor cognitive performance.
Damholdt MF; Borghammer P; Larsen L; Ostergaard K
Mov Disord; 2011 Sep; 26(11):2045-50. PubMed ID: 21638326
[TBL] [Abstract][Full Text] [Related]
18. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
Pagonabarraga J; Rodríguez-Oroz MC
Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679
[TBL] [Abstract][Full Text] [Related]
19. Characterizing mild cognitive impairment in Parkinson's disease.
Dalrymple-Alford JC; Livingston L; MacAskill MR; Graham C; Melzer TR; Porter RJ; Watts R; Anderson TJ
Mov Disord; 2011 Mar; 26(4):629-36. PubMed ID: 21287603
[TBL] [Abstract][Full Text] [Related]
20. Donepezil for cognitive decline following coronary artery bypass surgery: a pilot randomized controlled trial.
Doraiswamy PM; Babyak MA; Hennig T; Trivedi R; White WD; Mathew JP; Newman MF; Blumenthal JA
Psychopharmacol Bull; 2007; 40(2):54-62. PubMed ID: 17514186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
